Research & Studies

At bioMONTR Labs, we believe in nurturing and re-investing in the scientific community.  As a key opinion leader laboratory, we take the opportunity to publish and present the exciting results from many of our assay development efforts.  Summaries are provided below for a few of our recent publications/presentations. Contact us if you are interested in learning more.

Increasing the Performance of a Fully Automated Quantitative Assay for the Detection of Circulating HBV Pregenomic RNA

(presented at 2022 Digestive Disease Week in San Diego, CA.) Summary:  A presentation of the increased analytical performance of a fully automated assay for the detection and quantitation of hepatitis B pregenomic RNA in CHB patients.

Cerebrospinal fluid CXCL10 is associated with the presence of low-level CSF HIV during suppressive antiretroviral therapy

(Journal of Neuroimmunology 2021, 353:577493) Cerebrospinal fluid CXCL10 is associated with the presence of low-level CSF HIV during suppressive antiretroviral therapy.

Low-Level HIV RNA in Cerebrospinal Fluid and Neurocognitive Performance: A Longitudinal Cohort Study

(JAIDS 2021, 87(5):1196-1204) Low-Level HIV RNA in Cerebrospinal Fluid and Neurocognitive Performance: A Longitudinal Cohort Study

Increasing the performance of a fully automated quantitative assay for the detection of circulating HBV pregenomic RNA

(presented at 2021 HEP DART in Los Cabos, Mexico) Summary: A presentation of the increased analytical performance of a fully automated assay for the detection and quantitation of hepatitis B pregenomic RNA in CHB patients.

Hepatitis B pregenomic RNA: Performance of an Automated Real-Time Quantitative Assay

(presented at 2019 CVS in Savannah, GA) Summary:  A presentation of the analytical performance of a new assay for the detection and quantitation of hepatitis B pregenomic RNA in CHB patients.

Hepatitis B Pregenomic RNA Real-Time Quantitative Assay for Drug Development

(presented at 2019 HEP DART in Kauai, Hawaii.)  Summary:  A presentation of the analytical performance of a new assay for the detection and quantitation of hepatitis B pregenomic RNA in CHB patients.